Veloxis Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on therapies for organ transplantation, particularly immunosuppressive treatments used to prevent rejection in kidney and liver transplant recipients. The company engages in the development and commercialization of transplant-focused medicines.
Veloxis is known for marketing once-daily, extended-release tacrolimus in the United States under the Envarsus XR brand. The company operates as a wholly owned subsidiary of Asahi Kasei Group, following its acquisition in 2020, and collaborates across clinical development and commercialization to expand options in transplant medicine.
Brings acquired specialty-pharma units into a single global management to pursue niche immunology, nephrology, transplant and infectious disease markets; targets ¥300bn by FY2030.
Phase 2 trial compares pegrizeprument with tacrolimus in up to 120 de novo kidney transplant recipients; primary endpoints are safety, pharmacokinetics and pharmacodynamics.
Acquisition adds three antiviral assets - royalties from Prevymis, pritelivir (FDA Priority Review; PDUFA Q4 2026) and AIC468 - aims $500M revenue by 2030 and transplant/infectious-disease growth.
The acquisition enhances Asahi Kasei's pharmaceutical platform in severe infectious diseases, leveraging existing infrastructure for growth and expanding its treatment portfolio.
AK1960, a novel ETA receptor antagonist with a new core structure, shows high ETA selectivity and kidney-disease efficacy in animals and has advanced to Phase I for refractory diseases.
AK1960, an ETA receptor antagonist, enters Phase I trials for refractory diseases, leveraging Alchemedicine's HiSAP™ platform and partnerships with Calliditas and Veloxis.
